Smruti K. Patel · A multi-centre performance evaluation of a commercially developed liquid biopsy for the earlier detection of brain tumours
Follow
Article1 min read·Published Dec 2025

A multi-centre performance evaluation of a commercially developed liquid biopsy for the earlier detection of brain tumours

pubmed.ncbi.nlm.nih.gov shows its articles on its own site.

Read the article on pubmed.ncbi.nlm.nih.gov ↗

Article · Dec 2025 · 1 min read

In brief

In brief

The EMBRACE study evaluated a commercial liquid biopsy platform across 2,554 patients in Europe for earlier brain tumor detection in primary care settings. The test achieved 86% sensitivity for malignant brain cancers with 99% NPV, potentially enabling more efficient triage of patients with non-specific neurological symptoms before emergency presentation.

Written by the GCMD Library team from the article.

Smruti K. Patel

Background: Delayed diagnosis of brain cancer leads to two-thirds of patients receiving a diagnosis only after presenting to the emergency department with more severe symptoms or neurological deficits. A simple, rapid, liquid biopsy implemented in primary care could enable more efficient triage of patients with non-specific symptoms potentially related to brain cancer, prioritising patients for urgent brain imaging, and accelerating diagnosis. Patients And Methods: Presented is the international, multi-centre, observational Early and tiMely detection of BRAin CancEr (EMBRACE) study. Patients were prospectively recruited across seven sites in Europe, from the United Kingdom, Belgium, Sweden and Switzerland. The target population consisted of patients with symptoms potentially associated with brain cancer. Blood serum samples were analysed by the Dxcover® Brain Cancer Liquid Biopsy Platform. Test performance was assessed by comparison of the liquid biopsy result to diagnostic imaging. Results: Two thousand five hundred and fifty-four patients were enrolled across the seven collection sites; 2324 were deemed eligible and taken forward for test assessment. There were 697 brain tumours in total, of which 395 were malignant, and 1627 non-tumour diagnoses. Overall diagnostic performance for the primary objective was 86% sensitivity for brain cancer detection with 99% negative predictive value (NPV). Sensitivity for all brain tumours combined (malignant and benign) was 77%. Notably,

Statements in this article

  1. Two-thirds of brain cancer patients receive their diagnosis only after presenting to the emergency department with more severe symptoms or neurological deficits.

    EstablishedBackground
  2. The EMBRACE study prospectively recruited patients across seven sites in Europe from the United Kingdom, Belgium, Sweden and Switzerland.

    ResearchPatients And Methods
  3. The target population consisted of patients with symptoms potentially associated with brain cancer.

    ResearchPatients And Methods
  4. Test performance was assessed by comparison of the liquid biopsy result to diagnostic imaging.

    ResearchPatients And Methods
  5. 2554 patients were enrolled across the seven collection sites, with 2324 deemed eligible for test assessment.

    ResearchResults
  6. There were 697 brain tumours in total, of which 395 were malignant, and 1627 non-tumour diagnoses.

    ResearchResults
  7. The Dxcover® Brain Cancer Liquid Biopsy Platform demonstrated 86% sensitivity for brain cancer detection.

    ResearchResults
  8. The Dxcover® Brain Cancer Liquid Biopsy Platform demonstrated 99% negative predictive value for brain cancer detection.

    ResearchResults
  9. Sensitivity for all brain tumours combined (malignant and benign) was 77%.

    ResearchResults

Read it at the source ↗

Try
Intelligent Search· scoped to this article · not medical adviceSearch the whole library →
Only a few other public items share this field — go deeper there →
GCMD Library — educational content from recorded physician discussions, not medical advice.